

INSIDER




IN 2025, THE PELOTONIA COMMUNITY
RAISED A RECORD-BREAKING

\$29,212,864

TOTALING

\$339,074,826

ALL-TIME FUNDS RAISED SINCE
2009 TO ACCELERATE CANCER
RESEARCH AT THE OSUCCC – JAMES



Watch the 2025 fundraising
total reveal video

→ LETTER FROM THE CEO

FRIENDS OF PELOTONIA,

As we close out an extraordinary year, I find myself reflecting with equal parts hope, gratitude, and urgency. Cancer remains one of the greatest challenges of our time, and the need to invest boldly in research has never been more pressing. Yet this year, you — the entire Pelotonia community — responded with record-breaking determination. Together, we raised more than \$29.2 million, pushing our all-time total to an incredible \$339 million for innovative cancer research at The James at Ohio State.

These numbers are not just milestones; they represent lives changed and saved. They represent the belief that progress in cancer discovery cannot wait. As a cancer Survivor, I know personally that research is the reason people like me can make more memories, enjoy more milestones, and ultimately live life more fully.

This year, you showed up in every possible way. More than 12,000 participants from 49 states and 12 countries came

together with a single mission. Nearly 1,000 cancer Survivors rode, ran, hiked, and volunteered as living proof of what's possible when science advances. From advancements in immunotherapy to a clinical trial held through telemedicine at The James, we are seeing research unfold today that once felt impossible.

For all of this, I am grateful. Your passion, your generosity, and your unwavering belief in what we can accomplish together are pushing the pace of progress forward.

We'll celebrate this moment, but then we'll get back to work. Because the future we're building together is worth every ounce of effort.

With deep gratitude,



Joe Apgar
CHIEF EXECUTIVE OFFICER
PELOTONIA
—
Cancer Survivor



→ EVENT SPOTLIGHT

PELTONIA CONCLUDES 2025 WITH EXPANDED GRAVEL DAY EXPERIENCE AND NIGHT OF IMPACT CELEBRATION

GRAVEL DAY OCTOBER 4, 2025

Gravel Day made a spectacular return in 2025, enhanced by the introduction of the first-ever Trail Run/Hike. The festivities began Friday night at the Community Gathering at Snow Fork Event Center in Nelsonville, Ohio, with live music from the Hocking Hills Duo, food, drinks, and s'mores by the campfire. Gravel Day participants and spectators were invited to camp on-site Friday night in tents, cars, and RVs.

Now in its third year, Gravel Day has continued to grow participation, more than doubling over 2024, marking a major milestone for the event. Together, Gravel Day participants helped raise more than \$1 million, underscoring this event's momentum.

More than 280 Riders embarked on 11-, 25-, and 48-mile gravel routes, each highlighting Southeast Ohio's rolling hills and unpaved roads. Routes featured intense climbs through Athens County, with elevation gains ranging from 900 to 4,200 feet.

The inaugural Trail Run/Hike attracted more than 350 Runners and Hikers. Participants took on a 3.5-mile course surrounded by scenic forests and streams, ultimately completing 1,230 miles in total. A mass start kicked off the Trail Run/Hike, but participants could begin the route any time between 10 a.m. and 2:30 p.m., with the freedom to complete multiple laps for added distance. Some Riders opted to add the Trail Run/Hike after they completed their gravel cycling route for an extra challenge.

All participants and guests celebrated at the finish line with food, beverages, photo opportunities, and live music by Maria Carrelli, Jeremy Short, Buffalo Wabs & The Price Hill Hustle, and Corduroy Brown. Gravel Day would not have been possible without the help of more than 200 Volunteers offering first aid services, mechanical support, merchandise sales, snacks at rest stops, and more.



2025 PELOTONIA AWARDS



FIRST-YEAR RIDER AWARD:
LIA FROST



VOLUNTEER OF THE YEAR AWARD:
JAY HOBGOOD PHD
& RACHEL MAUK PHD



MARY HYATT COURAGE AWARDS:
GORDON HECKER &
BRANDON RADER



PELOTONIA LEGACY AWARD:
DWIGHT HURD



PELOTONIA KID OF THE YEAR AWARD:
NOLAN WINCE



COMMUNITY OF THE YEAR AWARD:
GRANVILLE



PELOTONIA-FUNDED RESEARCHER OF THE YEAR AWARD:
SAMEEK ROYCHOWDHURY MD, PHD



Read more about the 2025 awardees on our website



NIGHT OF IMPACT NOVEMBER 18, 2025

Pelotonia Night of Impact 2025 brought more than 1,400 community members together at KEMBA Live! for an inspiring evening of celebration, gratitude, and unforgettable moments. The event began with food, drinks, and a DJ set before Pelotonia CEO Joe Appgar took the stage to highlight all the ways this was a milestone year: more than 12,000 participants, record-breaking Survivor involvement, expanded event experiences, and a near doubling of Pelotonia Kids, with 11 rides raising more than \$167,000 for pediatric cancer research at Nationwide Children’s Hospital.

Joe then welcomed Kimryn Rathmell, MD, PhD, and CEO of the OSUCCC – James, to the stage. Dr. Rathmell reflected on her first Ride Weekend and the enormous impact Pelotonia has on accelerating cancer research discovery. She shared breakthrough examples of Pelotonia-funded research, from understanding T cell exhaustion to using artificial intelligence to help categorize lobular breast cancer, emphasizing that the community’s support fuels innovation every day.

The program recognized remarkable community members in seven categories, including two new awards that celebrated the growing reach of the movement: the Pelotonia Kid of the Year Award and the Community of the Year Award. After receiving the Pelotonia-Funded Researcher of the Year Award, Sameek Roychowdhury, MD, PhD, spoke about his groundbreaking work at the OSUCCC – James: the first nationwide telemedicine clinical trial, which is treating pancreatic cancer with a rare genetic mutation. You can read more about this exciting clinical trial on page 7.

The evening reached its peak with a high-energy on-stage video unveiling this year’s fundraising total. When the number flashed, announcing the largest single-year total in Pelotonia’s 17-year history, the room erupted in cheers, hugs, and celebratory streamers and balloons.



Watch the 2025 Night of Impact program



→ DONOR SPOTLIGHT

DEFYING LIMITS: WENDY CHIOJI'S LEGACY OF COURAGE AND GENEROSITY

MELE DEFY Charity Golf Tournament continues to raise money for cancer research in her memory

Wendy Chioji lived her life with boldness, joy, and purpose, leaving a legacy that has continued to inspire others after her passing in 2019. A dedicated Rider from 2015 to 2019, Wendy championed Pelotonia's mission with the same passion she brought to every part of her life. Whether on a bike, in a newsroom, or atop a mountain, she inspired everyone she met to defy the limits before them.

An Emmy Award-winning journalist, endurance athlete, and advocate for others, Wendy spent more than 25 years anchoring WESH 2 News in Orlando, becoming one of the region's most trusted and beloved voices.

Wendy's connection to cancer began in 2001, when she was diagnosed with Stage II breast cancer. Throughout chemotherapy and recovery, she remained remarkably active, continuing to run, bike, and race triathlons. Her transparency about her cancer journey and determination inspired viewers across Florida and beyond.

After completing treatment and being cancer-free, she left the news business a few years later to pursue her passions for travel, fitness, and adventure, eventually moving to Park City, Utah. However, in 2014, she received a second diagnosis: thymic carcinoma, a rare and aggressive cancer. True to form, she faced it with optimism and grit, undergoing surgery, chemotherapy, radiation, and later participating in clinical trials, including immunotherapy treatments at the National Institutes of Health. During this time, Wendy sought counsel and advice from Sameek Roychowdhury, MD, PhD, at the OSUCCC – James, as she explored potential therapy options, a connection that would later come full circle through her family's continued support of his research.

Still, Wendy refused to let cancer define her. She climbed Mt. Kilimanjaro (shown in photo on the right) and Mt. Fuji, completed IRONMAN triathlons, and traveled to all 50 states and seven

continents. Pelotonia Board Vice Chair Doug Ulman climbed Mt. Kilimanjaro with Wendy while she was in treatment, calling the experience incredibly special and a testament to her remarkable strength and determination. And every summer from 2015 to 2019, she returned to Ohio to ride in Pelotonia, raising funds for the cancer research that gave her and others more time. Her family proudly followed in her footsteps; her niece and sister-in-law have also ridden in Pelotonia, and other family members have come to Ride Weekend as enthusiastic supporters.

When Wendy passed away in 2019, her impact deepened. She left a generous estate gift to Pelotonia, the organization's first, ensuring that her passion for discovery and hope would continue fueling the fight against cancer.

Wendy's gift led to the creation of the Pelotonia Legacy Society, inspiring others to consider meaningful, lasting contributions through estate and planned giving. Her generosity continues to impact the Pelotonia community long after her lifetime.



PELTONIA LEGACY SOCIETY



The Pelotonia Legacy Society is a group of forward-thinking supporters who share a vision to provide for future generations of cancer patients and their families.

Planned giving, also known as legacy giving, allows you to have a lasting impact on cancer research while contributing to the long-term stability of Pelotonia's mission for years to come.

By pledging a planned gift, you commit to contribute to Pelotonia beyond your lifetime – and you will become part of the Pelotonia Legacy Society.

You will receive waived registration fees for Ride Weekend and Gravel Day, tickets to Opening Ceremony and Night of Impact, and an exclusive Pelotonia Legacy Society lapel pin. Thank you to the community members in the Pelotonia Legacy Society for their generosity and commitment!

Contact Philanthropy & Stewardship Manager, Erika Walker, at ewalker@pelotonia.org for more information.

COMMON PLANNED GIVING METHODS

- ➔ Bequests
- ➔ Life insurance policies
- ➔ Retirement plans and IRA rollovers
- ➔ Charitable gift annuities



Already included Pelotonia in your estate plans? Notify us of your gift by completing this form



Watch our recent webinar: *Your Legacy, Your Impact: Funding the Future of Cancer Research*

THE MELE DEFY CHARITY GOLF TOURNAMENT

Wendy's family continues her legacy through the MELE DEFY Charity Golf Tournament. Hosted by MELE Associates, Inc. under the leadership of her father, CEO Mel Chioioji, and her brother, President Al Chioioji, the event embodies her mantra: DEFY. MELE covers all event costs, ensuring that 100% of proceeds directly benefit Pelotonia.

The inaugural 2024 tournament raised more than \$70,000. This year's total reached \$105,000, supporting groundbreaking cancer research by Dr. Roychowdhury. Combined with Wendy's legacy gift, these funds have advanced a first-ever nationwide, decentralized clinical trial, which allows patients across the country to participate from their own hometowns, removing barriers to access.

"I am so grateful to be part of Wendy Chioji's journey. Her spirit is driving our cancer research," shared Dr. Roychowdhury, who attended this year's tournament to speak about how the funds are advancing his work. "Wendy's mantras of 'DEFY' and to 'Live Fearlessly' inspire our research team each day to be ambitious and legendary in our goals. This would not be possible without the funding support from her family and partners for this special golf outing. I am moved to know that Wendy's impact will have nationwide impact in every zip code through a novel decentralized clinical trial approach."

The tournament is as celebratory as it is impactful. Participants gather to raise funds and remember Wendy's infectious energy and zest for life.

"We put together the DEFY golf tournament to honor my sister and her incredible life," said Alan Chioioji. "Throughout her fight with cancer, raising funds and awareness of cancer research was always a priority for her. We thought it appropriate to continue to raise funds for Pelotonia, an organization she loved, and to share her story. I know she is smiling down at us and encouraging us to 'Live Fearlessly.'"

Wendy Chioji's story continues inspiring those who knew her and many who didn't. Through her extraordinary generosity and the ongoing efforts of her family and the Pelotonia community, her mantra lives on: DEFY fear. DEFY limits. DEFY cancer.


"FOR MORE THAN 20 YEARS, WENDY WAS A TREASURED FRIEND AND A REMARKABLE PRESENCE IN MY LIFE. I MISS HER EVERY DAY, AND OUR KIDS STILL TALK ABOUT HER WITH SUCH LOVE. HER LEGACY GIFT IS YET ANOTHER WAY SHE INSPIRES US TO LIVE BOLDLY AND GIVE GENEROUSLY."

DOUG ULMAN
PELTONIA BOARD VICE CHAIR



GLOBAL CANCER EXPERT JOINS OHIO STATE

Dr. Christian Rolfo leverages multi-cultural background for innovative care



When Christian Rolfo, MD, PhD, MBA, joined The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in August 2024, he brought decades of global experience and a vision to speed up the path from scientific discovery to patient care.

As director of the Division of Medical Oncology, Dr. Rolfo oversees nearly 100 physicians and scientists who treat a wide range of cancers, including lung, breast, gastrointestinal, skin and sarcoma, and who conduct research aimed at improving outcomes for patients everywhere.

Born in Córdoba, Argentina, Dr. Rolfo’s passion for service began early. His curiosity and compassion led him to pursue medicine, and his Italian roots drew him to Europe for further study and research. Over the years, he has worked in Spain, Belgium and the United States, becoming fluent in six

languages and gaining recognition as an international leader in oncology.

Dr. Rolfo, who also holds the Diane Nye and Michael Rayden Chair in Innovative Cancer Research, is known for pioneering work in liquid biopsy, which is a way to detect cancer through a simple blood test instead of a traditional tissue biopsy. By identifying tiny fragments of tumor DNA or circulating cancer cells, this approach offers a less invasive, faster and more precise way to diagnose and monitor cancer. His research has shaped international guidelines and expanded access to personalized treatments for patients with lung and thoracic cancers.

Now at the OSUCCC – James, Dr. Rolfo continues to push the boundaries of precision medicine, leading early-phase clinical trials and helping connect patients to innovative therapies. He emphasizes that such breakthroughs are possible only because of support from donors,



“This role enables me to contribute my background in different types of cancer and from different countries to the mission of the OSUCCC – James. Ohio State is not a place where you have to build a program from scratch, but is one with a long tradition of excellence that is striving for even greater renown and achievements.”

– CHRISTIAN ROLFO, MD, PHD, MBA

Professor and director of the Division of Medical Oncology at Ohio State, and member of the Translational Therapeutics Program at the OSUCCC – James

advocates and the Pelotonia community. In 2025, Dr. Rolfo contributed to this mission by actively raising funds for Pelotonia. Above all, he hopes his legacy will be one of turning science into hope by helping discoveries in the lab reach patients faster and by changing lives around the world.

The James



Read the full story on
Health & Discovery

A Novel Approach to Clinical Trials

- Every year, close to 64,000 people are diagnosed with pancreatic cancer.
- An estimated 1.5% of those have a fibroblast growth factor receptor (FGFR) mutation.
- A cancer this rare would make precision oncology treatments through the traditional clinical trial structure difficult; it would be expensive both for the organizer, requiring a broad net to participants, and the patients, who would have to travel to appointments and treatments.
- The cost of a traditional clinical trial in 50 locations could be \$20 million.
- This decentralized clinical trial will allow for full national coverage at just \$2 million.



“This is the first nationwide telehealth therapeutic clinical trial for cancer. It’s a new way of thinking and providing access to clinical trials.”

– **SAMEEK ROYCHOWDHURY, MD, PHD**
Medical oncologist and member of the Translational Therapeutics Program at the OSUCCC – James

→ RESEARCH SPOTLIGHT

EXPANDING ACCESS TO CANCER CARE NATIONWIDE THROUGH TELEHEALTH


Dr. Sameek Roychowdhury launches first-of-its-kind decentralized clinical trial for pancreatic cancer patients

For many people with cancer, traveling to receive the specialized care they need can be difficult. After the COVID-19 pandemic made telehealth more common, researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) are reimagining what’s possible for cancer patients everywhere.

Each year, nearly 64,000 people in the United States are diagnosed with pancreatic cancer. Most are diagnosed only after their disease has advanced, which makes them ineligible for surgical options that could cure it in earlier stages. In recent years, oncologists have discovered that some pancreatic cancer patients can benefit from targeted smart drugs, which are precision therapies designed to attack only the specific genetic mutations that fuel a cancer cell’s growth.

Building on these advances in precision oncology is Sameek Roychowdhury, MD, PhD, a medical oncologist and researcher at the OSUCCC – James. Dr. Roychowdhury’s new clinical trial takes the next leap forward: combining the power of genomic-driven treatment with the accessibility of telehealth. By connecting patients remotely with cancer experts and cutting-edge clinical research, his team is breaking down the geographic and logistical barriers that often prevent people from receiving advanced cancer care.

Dr. Roychowdhury believes that telehealth represents an operational innovation — a cost-effective, far-reaching model of care that can extend beyond the walls of major cancer centers. He hopes this clinical trial will



serve as a prototype for others, paving the way for more equitable access to research participation and the study of rare cancers.

A 15-year Pelotonia participant, High Roller and Peloton Captain of Team Buckeye – Sameek’s Geeks, Dr. Roychowdhury has raised over \$69,000 for Pelotonia. In 2025, he participated in the 100-mile route at Ride Weekend and the 25-mile route and Trail Run/Hike at Gravel Day. He is also a multiple-time recipient of Pelotonia-funded Idea Grants, and his long-standing dedication to cancer research earned him recognition as the 2025 Pelotonia-Funded Researcher of the Year awardee at the Night of Impact celebration.

The James



Listen to the full episode of *The James Cancer-Free World Podcast*



→ RESEARCHER SPOTLIGHT

DR. ERIC SINGER ADVANCES BREAKTHROUGHS IN UROLOGIC CANCER CARE AT THE OSUCCC – JAMES

At The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), Eric A. Singer, MD, MA, MS, is leading efforts to transform care for patients facing kidney cancer. As director of the Division of Urologic Oncology at Ohio State, Dr. Singer and his team are working to develop treatments that are both more effective and easier for patients to tolerate.

One of the division's most promising studies is exploring "histotripsy," a noninvasive technique that uses sound waves to destroy tumor tissue without surgery. The multicenter trial has already seen several successful procedures completed at the OSUCCC – James and could offer a less invasive alternative for some patients with kidney cancer.

Another ongoing study, known as the Cyto-KIK trial, is testing a

combination of targeted therapy and immunotherapy in people with metastatic kidney cancer. In this approach, patients receive medication before undergoing surgery to remove the primary tumor and resume systemic treatment afterward. Researchers believe that exposing patients to medicines before the tumor is removed may help the immune system better recognize and attack the disease after surgery.

Dr. Singer's group is also leading a new trial combining medications for patients at high risk of kidney cancer recurrence after surgery, an approach that builds on earlier single-drug studies and could establish a new standard of care.

In addition, the OSUCCC – James played a key role in a National Cancer Institute-led study that showed strong responses in patients with aggressive papillary kidney cancers using a similar



"I can't speak highly enough about the amazing team we have at the OSUCCC – James, and I'm privileged to be part of it. It's also incredibly rewarding to help patients who come to us from near and far with some of the most challenging problems in urology."

– ERIC A. SINGER, MD, MA, MS

Director of the Division of Urologic Oncology at Ohio State and member of the Translational Therapeutics Program at the OSUCCC – James

two-drug combination. Dr. Singer was a senior co-author of the study, which was published in the *New England Journal of Medicine*.

Beyond research, Dr. Singer is expanding the Division of Urologic Oncology, recruiting additional specialists and leading a fellowship program to train the next generation of experts. Most recently, he was named chair of the Board of Directors of the Kidney Cancer Association, which has been supporting patients and providers in the kidney cancer community since 1990.

Dr. Singer received Pelotonia funds for his research startup at the OSUCCC – James and is now a three-year Rider. He rides for his patients and for progress, embodying the connection between Pelotonia-funded research and discoveries that change lives.

The James



Read the full story on
Health & Discovery

UP TO THE CHALLENGE: INDIVIDUAL AND CORPORATE GOALS POWERING PELOTONIA



PROJECT GRIT TEAMMATES RYAN WILLIS, JOE SANDA, GRANT BURKS, LIAM BOTT, CAMERON BALLA, AND JOEL CRAIG COMPLETED A RELAY RUN ACROSS OHIO AS PELOTONIA CHALLENGERS, RAISING MORE THAN \$16,000.

Beyond riding or volunteering, Pelotonia supporters can fundraise in a uniquely personal way by becoming Challengers. This program lets participants design up to five custom goals with a minimum fundraising commitment of \$100. Challengers participate from anywhere in the world, and 100% of donations raised go directly to innovative cancer research at the OSUCCC – James. We're excited to share two inspiring stories of Challengers below.

PROJECT GRIT

Inspired by the Backyard Ultra movement, Ryan Willis meticulously planned a running relay race from Cincinnati to Cleveland. He then recruited five friends to join him on this journey, each committing to tackle approximately 52 to 56 miles.

All six teammates — Ryan, Joe Sanda, Grant Burks, Liam Bott, Cameron Balla, and Joel Craig — grew up in Columbus, Ohio, and shared personal connections to cancer. To give their effort greater meaning, they decided to fundraise for Pelotonia. They named the effort Project Grit, reflecting the determination, teamwork, and perseverance needed not only for their run but also for the fight against cancer.

On May 2, 2025, the group set out across Ohio. Each runner covered roughly three miles at a time while the others rested, refueled, or stretched in an RV driven by friends and family. The RV then

met the runner at the next exchange point, where teammates switched shifts and the relay continued north. Despite battling rain, the dark, and exhaustion, they stayed motivated and finished the 320-mile trek — jumping into Lake Erie just over 49 hours after leaving the Ohio River. Family and friends gathered at the finish to celebrate their remarkable achievement.

The team raised more than \$16,000 for Pelotonia. Ryan is considering another run next year, hoping to expand the group and inspire even more support for cancer research.

HI-IMPACT PROGRAM

Eight years ago, Rockbridge, a hospitality-centered investment firm, set out to engage its hotels in Pelotonia fundraising, and what began as a small idea has grown into a nationwide movement. The effort launched in 2018 as Make an

Impact, with 14 hotels raising \$19,000. Rebranded in 2021 as the HI-Impact Challenge (“HI” as an acronym for hospitality industry), it now unites more than 50 hotel and restaurant teams across the country to raise money for cancer research and has officially surpassed \$1 million in total contributions.

Each year, participating properties find creative ways to give back, from jeans-for-donations Fridays and yoga-and-mimosa classes to drag brunches and signature cocktails like the “Pelotonia Margarita.” Some hotel partners even collaborate with distributors to donate proceeds from beer or wine sales, demonstrating that small efforts multiplied across many teams can make a massive difference.

The program also celebrates the people behind the effort through the HI-Impact Heisman award, which honors unsung heroes in hospitality. The award finalists receive an all-expenses-paid trip to RTRX, an immersive leadership gathering that unites business leaders from across the country to spark ideas, connection, and action in support of cancer research through Pelotonia. This year’s winner, Debra from Alabama, was honored for her remarkable spirit of gratitude and generosity.

With more than \$350,000 raised in 2025, HI-Impact proves the hospitality industry’s power to create lasting change, one act of generosity at a time.



DEBRA, WHO WORKS AT A HOTEL IN ALABAMA, WAS AWARDED THE 2025 HI-IMPACT HEISMAN FOR HER OUTSTANDING CONTRIBUTIONS.



→ PARTNER SPOTLIGHT

ARIEL CORPORATION FUELS MISSION THROUGH SERVICE AND COMMUNITY SUPPORT

Every summer, the Pelotonia community unites around One Goal. Among those who make this mission possible, Ariel Corporation stands out, not only as a Funding Partner, but as a company that truly embodies what it means to show up with purpose.

This year, Ariel rallied more than 100 Volunteers at the Kenyon College finish line. To say the Pelotonia experience in Knox County would not have been the same without Ariel’s Volunteer presence would be an understatement. This location has traditionally been one of the hardest to staff due to its distance from Columbus, yet Ariel’s local community turned that challenge into a triumph.

Starting before sunrise and staying through teardown, the Ariel Volunteers enthusiastically greeted Riders as they crossed the finish line with cheers, water, and heartfelt encouragement. They also helped staff first aid and hydration stations, direct cyclists at intersections, and manage vehicle and pedestrian traffic.

Founded in Mount Vernon, Ohio, Ariel Corporation is a family-owned company specializing in gas compressors, led by CEO Alex Wright. The Wright family’s connection to Pelotonia is deeply personal. After the loss of Alex’s brother, Hunter Wright, to colon cancer in 2021, Ariel became a Pelotonia Funding Partner in 2024. The company also committed a generous two-year donation (2024–2025) to colorectal cancer research led by Richard Fishel, PhD, at the OSUCCC – James. In 2025, the family endured another profound loss with the passing of Karen Wright, Ariel’s former CEO and Chairman, to cancer.

With their first official Peloton launched in 2025, Ariel’s Volunteers and Riders embodied Pelotonia’s spirit. Their generosity, enthusiasm, and deep-rooted community pride demonstrate that Pelotonia’s success isn’t measured by miles ridden or dollars raised, but in the people who believe in a world without cancer and take action to make it a reality.

“ARIEL SHOWS UP FOR PELOTONIA BECAUSE SUPPORTING THIS MISSION IS PERSONAL FOR OUR PEOPLE AND DEEPLY CONNECTED TO WHO WE ARE AS A COMPANY. WHEN OUR COMMUNITY NEEDS US, WE BELIEVE IN BEING THERE, FULLY, HUMBLY, AND TOGETHER.”

ALEX WRIGHT
CEO, ARIEL CORPORATION



OUR MISSION

At Pelotonia, we're driven by our mission: to engage, inspire, and challenge a community committed to change the world by accelerating innovative cancer research.

THANKS TO OUR FUNDING PARTNERS, 100% OF EVERY DOLLAR RAISED IS DIRECTED TO INNOVATIVE CANCER RESEARCH AT THE OSUCCC – JAMES.

BENEFITING

The James



MAJOR FUNDING PARTNERS



Bath&BodyWorksSM



Huntington Bank

PEGGY & RICHARD
SANTULLI

VS&Co
VICTORIA'S SECRET & CO.

SUPPORTING FUNDING PARTNERS



THE HASLAM³
FOUNDATION



Safelite

NOTABLE FUNDING PARTNERS



DIAMOND HILL



OUR BOARD

Robert H. Schottenstein

BOARD CHAIR

Chairman and CEO, M/I Homes, Inc.

Doug Ulman

VICE CHAIR

Founder, Orli

Carol R. Bradford, MD, MS, FACS

Dean, College of Medicine and Vice President for Health Sciences, The Ohio State University Wexner Medical Center

Renee Cacchillo

President & CEO, Safelite® Group

Victor Crawford

Board Member, The Hershey Company

Cindy Hilsheimer

Managing Principal, BeecherHill

Raphael E. Pollock, MD, PhD, FACS

Director, The Ohio State University Comprehensive Cancer Center

W. Kimryn Rathmell, MD, PhD

CEO, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Daniel Rosenthal

President & CEO, Global Critical Logistics

Steve Steinour

Chairman, President and CEO, Huntington Bancshares Inc.

Abigail Wexner

CEO, Whitebarn Associates

PELTONIA®

2281 Kenny Road
Suite 450
Columbus, OH 43210

pelotonia.org

PELTONIA INSIDER

ISSUE 5
FALL 2025

Celebrating new innovations in cancer research at the OSUCCC – James made possible in part by Pelotonia funding

FEATURED INSIDE:



→ DONOR SPOTLIGHT:
**DEFYING LIMITS: WENDY
CHIOJI'S LEGACY OF
COURAGE AND GENEROSITY**

4



→ RESEARCH SPOTLIGHT:
**EXPANDING ACCESS TO
CANCER CARE NATIONWIDE
THROUGH TELEHEALTH**

7



→ PARTNER SPOTLIGHT:
**ARIEL CORPORATION FUELS
MISSION THROUGH SERVICE
AND COMMUNITY SUPPORT**

10



PELTONIA® ENDING CANCER

JOIN US FOR PELTONIA 2026!

REGISTRATION OPENS MARCH 4
OPENING CEREMONY — JULY 31
RIDE WEEKEND — AUGUST 1-2
GRAVEL DAY — FALL 2026